PloS one

How two diabetes drugs may differ in their link to osteoarthritis risk

Updated

Abstract

The comparative impact of SGLT2 inhibitors and GLP-1 receptor agonists on osteoarthritis risk in type 2 diabetes patients remains unclear.

  • SGLT2 inhibitors and GLP-1 receptor agonists may offer metabolic and anti-inflammatory benefits.
  • These benefits could potentially influence the risk of osteoarthritis in patients with type 2 diabetes.
  • The study aims to evaluate and compare the effects of these two drug classes on osteoarthritis incidence.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

NO authors have competing interests.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free